Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Cronos Group Inc. Is Crushing It Again Today

By Keith Speights - Sep 19, 2018 at 3:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cronos Group appears to be riding the wave generated by heavy investor interest in its fellow marijuana grower, Tilray.

What happened

Shares of Cronos Group Inc. ( CRON 4.40% ) were 22.8% higher as of 2:49 p.m. EDT Wednesday. The Canadian marijuana grower announced a partnership with Aleafia Health to conduct a study evaluating the use of medical cannabis in treating insomnia and daytime sleepiness. But this news probably wasn't the main reason behind Cronos Group's big jump.

The more likely factor for Cronos Group's big move today was a halo effect resulting from Tilray's ( TLRY ) even bigger gain of more than 40%. An interview on CNBC Tuesday evening with Tilray CEO Brendan Kennedy sparked excitement about the prospects for Tilray and for the cannabis industry overall.

A marijuana leaf in front of a pile of $100 bills.

Image source: Getty Images.

So what

Tilray CEO Brendan Kennedy told CNBC's Jim Cramer that he thinks pharmaceutical and alcoholic beverage companies need to hedge their bets by partnering with cannabis companies. He also predicted that there will be "multiple hundred-billion-dollar companies" in the cannabis industry.

That kind of talk is music to the ears of investors looking at Cronos Group. The company doesn't have a major partnership with a beverage company or drugmaker yet, but it would likely be on the short list of any major players looking to find a cannabis partner. 

Cronos Group's announcement of a partnership to study medical cannabis as a potential treatment for insomnia and daytime sleepiness underscores the possibilities for the company in the healthcare space. Progress on this front could arguably make Cronos even more attractive to major pharmaceutical companies.

And if Kennedy is right that there will be several marijuana stocks worth $100 billion or more, there's a reasonable chance that Cronos could be one of them. The company currently ranks No. 5 in terms of market cap among Canadian marijuana growers.

Now what

Investors need to remember, though, that Cronos Group doesn't have a deal in hand with any large company yet. There are several other big Canadian marijuana growers in that category as well -- and they could be higher on the list for potential partners than Cronos is.

Also, Brendan Kennedy's prediction of several marijuana companies with market caps of $100 billion or more hinges on the global cannabis market growing to $150 billion. Actual global cannabis sales probably won't come anywhere close to that level over the next few years.

Cronos Group could certainly move higher, especially if the Canadian recreational marijuana market enjoys a bigger launch than expected or if the company snags a lucrative partnership with a major player outside of the cannabis industry. Investors should be prepared for a potentially bumpy ride, though.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
$4.51 (4.40%) $0.19
Tilray Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.